Industry Outlook

The pigmentation disorders treatment market is set to reach US$ 12,313.2 Mn by 2030 from US$ 6,777.4 Mn in 2021 showcasing a steady growth at a compound annual growth rate (CAGR) of 6.9% during the forecast period from 2023 to 2030. The American Association for Pediatric Ophthalmology and Strabismus (AAPOS) claims that 1 in 17,000 people suffer with some form of Albinism. Vitiligo is a lifelong condition and there is no permanent cure; however, exposure to UVA and UVB phototherapy stimulates the growth of melanocytes on the skin patches and treats hypopigmentation to a certain extent. In the present scenario, pharmaceutical manufacturers are using topical creams in combination such as adapalene/benzoylperoxide, adapalene/clindamycin for the treatment of face dark spots created due to acne vulgaris. Currently, imiquimod cream (MEDA Pharma GmbH & Co. KG) is in phase 3 clinical trials being tested for better clinical outcomes in the treatment of Solar Lentigines.

North America currently dominates the pigmentation disorders market on account of growing melasma incidence in pregnant women. Existence of well-developed healthcare infrastructure and presence of major players prove beneficial in treating patients suffering with post inflammatory hyperpigmentation in North America. The pigmentation disorders treatment market is growing at a rapid pace in Asia Pacific on account of key drivers such as competition exerted by local manufacturers. The other factors promoting growth are supportive regulatory norms favoring growth of topical drugs, and rise in per capita income.

Rising incidence of skin hyperpigmentation to cater excellent growth for topical drugs

In the current scenario, topical drugs are dominating the treatment type segment owing to better clinical outcomes in patients suffering with pigmentation disorders. The topical drugs commonly prescribed throughout the globe are azelaic acid, hydroquinone, L-ascorbic acid etc. Chemical peels have found prominence in the last 2 decades to treat facial hyperpigmentation disorders. They are effective in treating face wrinkles caused due to aging and harmful sun light, improve the appearance of mild scars and treat dark spots caused due to acne. Dermabrasion has developed a niche market owing to its popularity in solving facial defects such as pox scars, accident scars, age spots and dull skin. Rise in per capita income and upgraded lifestyle are the driving factors for the growth of phototherapy and laser therapy for treating pigmentation disorders. However the high costs associated with photo and laser therapy is a limitation for its market growth.

Higher incidence of melasma in women post pregnancy will result in impressive double-digit growth

Melasma often known as chloasma occurs in 90% of the pregnant women. It results in discoloration of the skin in patches usually in the forearms, chin, cheeks, bridge of the nose and forehead. The incidence of melasma is higher in dark skinned people, in comparison to fair skinned people. The chief factors responsible for the occurrence of melasma in women are hormones, pregnancy and use of birth control pills. Melasma results in huge demand for topical drugs, chemical peels and microdermabrasion for dermal treatment. Post inflammatory hyperpigmentation is set to register growth at a rapid pace due to key factors such as increasing number of domestic accidents resulting in dermal burns and skin tissue abrasion, resulting in hyperpigmentation due to excess melanin production during healing process.

Increasing competition from local players in Asia Pacific will result in tremendous growth during the forecast period

North America accounts for 42% of the market share and thus dominates the global pigmentation disorders treatment market. The important parameters responsible for the burgeoning growth of North America is the presence of market leaders pioneering in dermatology products such as Galderma S.A., RXi Pharmaceuticals Corporation and Vivier Pharma. Rising number of patients suffering with skin pigmentation disorders due to harmful exposure to UV radiation and increasing public awareness related to skin diseases propels the pigmentation disorders treatment market growth in Europe. Asia Pacific is set to register faster growth owing to the competition created by local players. Increase in per capita income and enhanced funding by the pharmaceutical companies in the research and development to enhance the quality and efficacy of dermal products impose a positive effect on the market growth in Asia Pacific.

In order to understand the prevailing market trend and quantitative analysis the market assessment of pigmentation disorders treatment market is performed. Product portfolio is helpful in giving valuable information of the medicines being currently used for the treatment of pigmentation disorders. The major players spearheading the pigmentation disorders treatment market are ALLERGAN, Bayer AG, Galderma S.A., EpiPharm AG, Pierre Fabre Laboratories, La-Roche Posay, Obagi Cosmeceuticals LLC, RXi Pharmaceuticals Corporation, SkinCeuticals and Vivier Pharma.

Historical & Forecast Period

This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Pigmentation Disorders Treatment market are as follows:

• Research and development budgets of manufacturers and government spending
• Revenues of key companies in the market segment
• Number of end users and consumption volume, price and value.
• Geographical revenues generate by countries considered in the report
• Micro and macro environment factors that are currently influencing the Pigmentation Disorders Treatment market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Key questions answered in this report

• What are the key micro and macro environmental factors that are impacting the growth of Pigmentation Disorders Treatment market?
• What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
• Estimated forecast and market projections up to 2032.
• Which segment accounts for the fastest CAGR during the forecast period?
• Which market segment holds a larger market share and why?
• Are low and middle-income economies investing in the Pigmentation Disorders Treatment market?
• Which is the largest regional market for Pigmentation Disorders Treatment market?
• What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
• Which are the key trends driving Pigmentation Disorders Treatment market growth?
• Who are the key competitors and what are their key strategies to enhance their market presence in the Pigmentation Disorders Treatment market worldwide?